Trial Profile
A Retrospective study of Cangrelor as bridging strategy in patients with coronary artery disease undergoing cardiac and non-cardiac surgery
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 May 2018
Price :
$35
*
At a glance
- Drugs Cangrelor (Primary)
- Indications Coronary arteriosclerosis
- Focus Therapeutic Use
- 07 May 2018 New trial record
- 12 Mar 2018 Results presented at the 67th Annual Scientific Session of the American College of Cardiology